Beam Therapeutics Receives RMAT Designation from U.S. FDA for BEAM-302 in Treatment of AATD
Tuesday, May 13, 2025
Beam Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302.
AATD is caused by mutations in the SERPINA1 gene, most commonly the PiZ variant, which leads to low circulating levels of functional AAT and accumulation of misfolded protein in the liver. This results in lung damage due to unregulated neutrophil elastase activity and liver damage due to toxic build-up of the defective protein.
BEAM-302 aims to offer a one-time treatment by directly correcting the underlying genetic mutation. By restoring production of functional AAT protein and reducing harmful protein aggregates, the therapy could address both lung and liver complications of AATD. Unlike current therapies, which rely on protein replacement and do not prevent disease progression, BEAM-302 may offer a more comprehensive and lasting solution.
Current treatment options are limited and non-curative, highlighting the need for innovative approaches such as BEAM-302.
This investigational therapy is aimed at treating alpha-1 antitrypsin deficiency (AATD), a genetic condition affecting the lungs and liver.
BEAM-302 is a liver-targeted lipid nanoparticle (LNP) formulation containing a guide RNA and an mRNA that encodes a base editor. It is designed to correct the PiZ mutation in patients with AATD. Individuals with two copies of this mutation (PiZZ genotype) represent the majority of those suffering from severe forms of the disease.
RMAT designation is intended to support the development of regenerative therapies for serious or life-threatening diseases where there is an unmet medical need. It offers benefits such as early and frequent interactions with the FDA, potential for accelerated approval based on surrogate endpoints, rolling review of regulatory submissions, and priority review eligibility.
The company also plans to begin enrolling AATD patients with mild to moderate liver disease in the second half of 2025.
Source: beamtx.com
